Bayer has secured a significant victory at the Supreme Court, removing a substantial obstacle in its effort to settle thousands of claims linking its Roundup herbicide to cancer.
The ruling comes as the German pharmaceutical and agricultural giant continues working through a massive litigation docket. Tens of thousands of plaintiffs have alleged that exposure to Roundup caused various forms of cancer, spawning legal battles that have stretched across multiple jurisdictions and courts.
The Supreme Court's decision bolsters Bayer's position as it negotiates resolution of these outstanding claims. The company has been attempting to reach comprehensive settlements that would resolve the broader litigation, a process complicated by the sheer volume of cases and the divergent outcomes in earlier proceedings.
The outcome represents progress for Bayer in managing one of the most consequential product liability disputes in recent corporate history. The company acquired Roundup's parent company Monsanto in 2018, inheriting the legal exposure along with the acquisition.
Lower courts had previously ruled against the company in several high-profile cases, with juries awarding substantial damages to plaintiffs. Those verdicts created significant pressure on settlement negotiations and raised questions about the company's long-term financial exposure.
The Supreme Court's decision removes one avenue for further litigation and allows Bayer to consolidate its approach to resolving the remaining claims more efficiently. Roundup remains one of the world's most widely used herbicides, and the litigation has cast a shadow over its continued use and sales prospects globally.
Author James Rodriguez: "This is a meaningful win for Bayer, but it doesn't erase years of courtroom losses or the fundamental questions hanging over Roundup's future."
Comments